Updated: Reunion’s psychedelic approach in postpartum depression clears Phase 2 trialnews2025-08-18T11:37:06+00:00August 18th, 2025|Endpoints News|
Pfizer’s sickle cell drug candidate fails Phase 3 trialnews2025-08-15T18:11:26+00:00August 15th, 2025|Endpoints News|
Schrödinger ends work on blood cancer drug after two patient deathsnews2025-08-14T14:52:12+00:00August 14th, 2025|Endpoints News|
NIH backs away from mRNA research, claiming lack of public trustnews2025-08-13T19:32:31+00:00August 13th, 2025|Endpoints News|
Vedanta’s microbiome therapy fails Phase 2, company lays off 20%news2025-08-13T18:44:59+00:00August 13th, 2025|Endpoints News|
CytomX discloses patient death in study of ADC in colorectal cancernews2025-08-13T18:44:04+00:00August 13th, 2025|Endpoints News|
Padcev-Keytruda combo shows ‘compelling’ survival results in bladder cancernews2025-08-12T18:42:04+00:00August 12th, 2025|Endpoints News|
Sarepta details Elevidys’ liver toxicity data and plans for safety studynews2025-08-12T15:25:39+00:00August 12th, 2025|Endpoints News|
Endpoints livestream: What RFK’s exile of mRNA says about MAHA and biotechnews2025-08-12T12:00:25+00:00August 12th, 2025|Endpoints News|
Novartis’ antibody ianalumab clinches another Phase 3 win, this time in a rare blood diseasenews2025-08-12T11:12:37+00:00August 12th, 2025|Endpoints News|
